Navigating the Biosimilars Landscape: Regulatory, Clinical, Market, Patient, and Provider Perspectives and Future Directions

Sufiyan Ansari*, Dr. G.J. Khan

J.I.I.U’S Ali-Allana College of Pharmacy Akkalkuwa, Dist.- Nandurbar (425415) Maharashtra, India.

Abstract: Biosimilars are becoming an increasingly important part of the global pharmaceutical market due to their potential to improve patient access to life-saving biologic medicines while reducing healthcare costs. In this review article, we summarize key points regarding the regulatory landscape, clinical studies, market landscape, patient and provider perspectives, and future directions for biosimilars. Keywords: Biosimilars, Biologics, Approval process, Efficacy, Safety.

Corresponding Author: Sufiyan Ansari Email ID: ansarisufiyan038@gmail.com    Contact: 9323158918

Article History Received:        15/09/2023 Accepted:        25/10/2023 Published:       01/11/2023

 

 

 

 

 

 

 

 

 

 

 INTRODUCTION:

Biosimilars are a type of biological product that are highly similar to an already approved reference product, with no clinically meaningful differences in terms of safety, purity, and potency. They are becoming increasingly important in healthcare as they offer a cost-effective alternative to expensive biologic drugs, which can account for a significant proportion of healthcare spending.

According to a report published by the Pharmaceutical Research and Manufacturers of America (PhRMA) in 2020, (1) biologics have revolutionized the treatment of many diseases, offering new and effective therapies for patients with serious and chronic conditions. The report highlights that biologic now account for 40% of all new drug approvals in the US, and that the number of biologic medicines in development has been steadily increasing over the past decade.

Biosimilars have a huge potential to reduce healthcare costs and increase patient access to biologic therapies. The growing market for biosimilars presents a significant opportunity for cost savings in healthcare, while maintaining the same level of safety and efficacy as their reference products. The increasing adoption of biosimilars is expected to promote competition in the market, driving down the prices of biologic drugs and improving access to treatment for patients.

According to a report by the IMS Institute for Healthcare Informatics, the global biosimilars market is expected to grow to $15 billion by 2025, representing a significant opportunity for cost savings in healthcare (IMS Institute for Healthcare Informatics, 2020) (2). Biosimilars are also expected to contribute to the sustainability of healthcare systems by increasing patient access to important biologic therapies and reducing the burden on healthcare budgets. (3)

Several studies have demonstrated the potential for biosimilars to reduce healthcare costs without compromising patient outcomes. A systematic review and meta-analysis of randomized controlled trials comparing biosimilars and their reference products found no significant differences in terms of safety, efficacy, or immunogenicity (4).

Another study analyzing the impact of biosimilars on healthcare costs in Europe found that the use of biosimilars resulted in a 31% reduction in drug costs for the European Union (EU) healthcare systems (5).

In recent years, there has been a significant increase in the number of biosimilars approved by regulatory agencies worldwide. According to a report published by the International Generic and Biosimilar Medicines Association (IGBA) in 2021, there are currently more than 90 biosimilars approved in the European Union, and more than 30 in the United States. Additionally, there are a growing number of biosimilars approved in other regions, including Canada, Japan, and South Korea.

The increasing number of biosimilar approvals reflects the growing recognition of the value of these medicines in healthcare. Biosimilars offer a way to increase access to important biologic therapies while potentially reducing healthcare costs. They are subject to rigorous regulatory requirements to ensure that they are highly similar to their reference biologics in terms of safety, efficacy, and quality. This process can require extensive analytical and clinical testing, and as such, the approval of biosimilars by regulatory agencies represents a significant milestone in their development.

Methodology:

The methods used for designing this review is as follows:

Ø  Research question: The research question for this review article is: "What is the current state of knowledge on biosimilars, including their development, regulation, and clinical use?"

Ø  Literature search: A comprehensive literature search using relevant databases such as PubMed, Embase, and Cochrane Library was conducted. Search terms could include "biosimilars," "biosimilar development," "regulation of biosimilars," "clinical use of biosimilars," and related terms. Relevant articles that are published in and after 2020 were selected. The search includes both original research articles and review articles published in the last four years.

Ø  Study selection: Only those retrieved articles that are relevant to the research question were selected. Inclusion criteria includes articles that focus on biosimilar development, regulatory frameworks, clinical trials, or real-world clinical use. Exclusion criteria could include articles that focus on other types of biologics, such as originator biologics, or articles that are not relevant to the research question.

Ø  Data extraction: Relevant data from the selected articles were extracted, including study design, sample type, regulatory requirements, outcomes, and conclusions. Patterns found in these data, that were relevant to the research question were carefully studied.

Ø  Data synthesis and analysis: The extracted data was be synthesized and analyzed using a narrative approach. The findings are organized and presented thematically, with key concepts.

Ø  Conclusion: A detailed conclusion of the data summarized was included.

Ø  References: A list of relevant references were included in Vancouver style of references.

 

Advantages of biosimilars:

1. Biosimilars have the potential to increase patient access to important biologic therapies (6).
2. Biosimilars may offer cost savings compared to their reference products, which can be particularly important for high-cost biologics (7).
3. Biosimilars can contribute to a more competitive marketplace, which may drive down prices and increase innovation.
4. Biosimilars can help to address issues of drug shortages, particularly in the case of critical biologic medicines.
5. Biosimilars may offer a similar safety and efficacy profile to their reference products, as demonstrated through extensive analytical and clinical testing.

 

Limitations:

1. Biosimilars can face challenges related to naming and interchangeability, which may impact physician and patient acceptance.
2. The development and manufacturing of biosimilars can be complex and costly, which may limit the number of companies able to enter the market (5).

Regulatory landscape:

Biosimilars are biological products that are highly similar to an already approved reference product in terms of quality, safety, and efficacy. To ensure the safety and efficacy of these products, regulatory authorities have established specific requirements for their approval in different regions of the world.

1.                  United States:

In the US, the approval process for biosimilars is regulated by the Food and Drug Administration (FDA). Biosimilar applicants are required to demonstrate that their product is highly similar to the reference product in terms of structure, function, and efficacy. The FDA also requires biosimilar applicants to conduct clinical trials to demonstrate the safety and efficacy of their product. Additionally, the FDA has established guidelines for demonstrating interchangeability, which allows a biosimilar to be substituted for the reference product without the involvement of a healthcare provider (8).

2.                  Europe:

In Europe, the European Medicines Agency (EMA) is responsible for regulating the approval of biosimilars. To be approved, a biosimilar must demonstrate comparability to the reference product in terms of quality, safety, and efficacy. The EMA requires a comprehensive comparability exercise, which includes analytical, non-clinical, and clinical studies. The clinical studies should be conducted in a sensitive patient population, and the endpoints used should be relevant and clinically meaningful. The EMA also requires that the biosimilar and the reference product have the same pharmaceutical form and strength (9).

3.                  Asia:

In Asia, regulatory requirements for biosimilars vary by country. In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) is responsible for regulating the approval of biosimilars. The PMDA requires that the biosimilar demonstrate similarity to the reference product in terms of quality, safety, and efficacy. The PMDA also requires clinical trials to be conducted in a sensitive patient population. In South Korea, the Ministry of Food and Drug Safety (MFDS) regulates the approval of biosimilars. The MFDS requires a comprehensive comparability exercise, including analytical, non-clinical, and clinical studies. The clinical studies should be conducted in a sensitive patient population, and the endpoints used should be relevant and clinically meaningful (10).

 

The regulatory approaches for biosimilar approval differ across regions, and these differences can impact the development and availability of biosimilars.

1.                  United States:

In the US, the regulatory approach for biosimilar approval emphasizes the importance of demonstrating interchangeability with the reference product. The FDA has established guidelines for demonstrating interchangeability, which can promote competition and increase patient access to lower-cost biosimilars. However, the high regulatory barriers for interchangeability may also slow the development and approval of biosimilars (8).

2.                  Europe:

In Europe, the regulatory approach for biosimilar approval emphasizes the importance of a comprehensive comparability exercise that includes non-clinical and clinical studies. This approach can increase the confidence in the similarity between the biosimilar and reference product, which can promote market uptake and increase patient access to lower-cost biosimilars. However, the high regulatory requirements can also slow the development and approval of biosimilars (9).

3.                  Asia:

In Asia, the regulatory approaches for biosimilar approval differ by country. In Japan, the regulatory approach emphasizes the importance of clinical trials in a sensitive patient population, which can increase the confidence in the safety and efficacy of the biosimilar. This approach can promote market uptake and increase patient access to lower-cost biosimilars. In South Korea, the regulatory approach emphasizes the importance of a comprehensive comparability exercise, which can increase the confidence in the similarity between the biosimilar and reference product. This approach can promote market uptake and increase patient access to lower-cost biosimilars (10).

Clinical studies:

Recent clinical studies have provided important insights into the pharmacokinetics, pharmacodynamics, and immunogenicity of biosimilars, which are critical factors for demonstrating their safety and efficacy.

1.    Pharmacokinetics:

▪       Several recent clinical studies have evaluated the pharmacokinetics of biosimilars and their reference products.

▪       A study published in 2023 evaluated the pharmacokinetics of a biosimilar rituximab in patients with follicular lymphoma and found no clinically relevant differences in pharmacokinetics between the biosimilar and reference product (11).

▪       These studies suggest that biosimilars can demonstrate similar pharmacokinetics to their reference products.

2.    Pharmacodynamics:

▪       Pharmacodynamic studies have also been conducted to evaluate the efficacy of biosimilars.

▪       For example, a study published in 2020 evaluated the efficacy of a biosimilar bevacizumab in patients with advanced non-squamous non-small cell lung cancer and found no significant differences in efficacy between the biosimilar and reference product (12).

▪       These studies suggest that biosimilars can demonstrate similar pharmacodynamic properties to their reference products.

3.    Immunogenicity:

▪       Immunogenicity is an important consideration for biosimilar development and approval, as it can impact safety and efficacy.

▪       Several recent studies have evaluated the immunogenicity of biosimilars and their reference products.

▪       For example, a study published in 2020 evaluated the immunogenicity of a biosimilar adalimumab in healthy volunteers and found no significant differences in immunogenicity between the biosimilar and reference product (13).

▪       Similarly, a study published in 2021 evaluated the immunogenicity of a biosimilar trastuzumab in patients with HER2-positive breast cancer and found no significant differences in immunogenicity between the biosimilar and reference product (14).

▪       These studies suggest that biosimilars can demonstrate similar immunogenicity to their reference products.

 

Overall, recent clinical studies have provided important insights into the pharmacokinetics, pharmacodynamics, and immunogenicity of biosimilars. These studies suggest that biosimilars can demonstrate similar properties to their reference products, which can increase confidence in their safety and efficacy.

Market landscape:

In recent years, the global biosimilars market has experienced significant growth, with increasing competition among biosimilar manufacturers.

According to a report by Grand View Research, Inc., the global biosimilars market size was valued at USD 9.1 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 28.3% from 2021 to 2028. This growth can be attributed to several factors, including the expiration of patents on several blockbuster biologics, the increasing demand for affordable biologic therapies, and the growing acceptance of biosimilars among healthcare providers and patients (15).

❖        Competition among biosimilar manufacturers:

As the biosimilars market continues to grow, competition among biosimilar manufacturers has intensified. According to a report by IQVIA Institute for Human Data Science, there were over 80 biosimilar development programs underway in 2020, with the majority focused on monoclonal antibodies. The report also noted that while the number of approved biosimilars has increased in recent years, there is still significant variation in approval processes and timelines across regions, which can impact the ability of manufacturers to bring biosimilars to market (16).

In addition, some biosimilar manufacturers have adopted different strategies to gain a competitive advantage.

For example, some manufacturers have focused on developing biosimilars for niche indications or for biologics that have a smaller patient population, while others have focused on developing biosimilars with improved dosing or administration compared to the reference product.

Overall, the global biosimilars market is expected to continue to grow in the coming years, with increasing competition among biosimilar manufacturers. This competition could result in greater availability and affordability of biologic therapies for patients, but may also lead to challenges for manufacturers as they navigate the complex regulatory landscape and seek to differentiate their products in a crowded market.

Pricing and reimbursement policies play a crucial role in shaping the biosimilars market, as they can affect the affordability and accessibility of these drugs to patients. The high cost of biologic drugs has been a major barrier to patient access, and biosimilars offer a more cost-effective alternative. However, without appropriate pricing and reimbursement policies, biosimilars may not be able to achieve widespread adoption.

In recent years, many countries have implemented policies to encourage the use of biosimilars by setting lower prices for these drugs compared to their reference biologics. For example, the European Union (EU) has been a leader in promoting biosimilars adoption, with a centralized system for approving these drugs and policies that incentivize their use. These policies have been successful in increasing the uptake of biosimilars and reducing healthcare costs in countries like Germany and France (17).

In the United States, pricing and reimbursement policies for biosimilars remain complex and vary by payer and state, which can make it difficult for these drugs to compete with their reference biologics. However, recent policy changes, such as the Centers for Medicare & Medicaid Services' (CMS) Biosimilar Payment and Required Incentives for Savings (PIRS) Model, have aimed to increase biosimilar uptake by encouraging competition and lowering costs for patients (18).

The COVID-19 pandemic has also highlighted the need for affordable and accessible treatments, including biosimilars. Biosimilars have the potential to play a critical role in improving patient access to treatments and reducing healthcare costs, particularly as healthcare systems grapple with the economic impact of the pandemic (19). For example, biosimilars of adalimumab, a biologic used to treat autoimmune diseases, have recently been approved in the EU, which could help to lower healthcare costs and improve patient access to treatment (20).

Overall, pricing and reimbursement policies are crucial for shaping the biosimilars market and improving patient access to affordable treatments.

Patient and provider perspectives:

Patients and healthcare providers have varying perceptions about biosimilars, which can influence their attitudes towards their use. While biosimilars have been shown to be safe and effective alternatives to reference biologics, concerns about their safety, efficacy, and quality may impact their adoption.

Several studies have explored the attitudes of patients and healthcare providers towards biosimilars. Patients often have limited knowledge and understanding of biosimilars, which can lead to skepticism about their safety and efficacy. A survey of patients in the United States found that many were hesitant to switch to biosimilars due to concerns about their safety and efficacy, as well as a lack of trust in the approval process for these drugs (21).

Healthcare providers, on the other hand, may have concerns about the quality and consistency of biosimilars. A survey of healthcare providers in the European Union found that many were uncertain about the quality and clinical performance of biosimilars, which may impact their willingness to prescribe these drugs. Additionally, providers may have concerns about the impact of biosimilars on patient outcomes and the potential risks of switching patients from reference biologics to biosimilars (22).

Despite these concerns, there is growing evidence that biosimilars are safe and effective alternatives to reference biologics. A meta-analysis of 19 randomized controlled trials found no significant differences in safety or efficacy between biosimilars and their reference biologics in patients with rheumatoid arthritis (23). Another study found that switching from a reference biologic to a biosimilar was not associated with an increased risk of adverse events or treatment failure in patients with inflammatory bowel disease (24).

Education and communication about biosimilars may play a critical role in improving patient and provider perceptions of these drugs. For example, a study of healthcare providers in the United States found that education and awareness campaigns were effective in improving provider knowledge and attitudes towards biosimilars. Additionally, patient education and engagement may be key to increasing patient trust and confidence in biosimilars. (25)

Overall, perceptions of patients and healthcare providers on biosimilars can impact their adoption and use. While concerns about safety and efficacy may exist, growing evidence suggests that biosimilars are safe and effective alternatives to reference biologics. Education and communication about biosimilars may be critical to improving perceptions and increasing adoption of these drugs.

Recent initiatives have been launched to increase patient and provider education on biosimilars and their potential benefits. These initiatives aim to address the knowledge gaps and concerns about biosimilars, and promote their safe and effective use.

 

 

In the United States, the FDA has launched several initiatives to educate healthcare providers and patients on biosimilars. The FDA's Biosimilars Education and Outreach Campaign includes webinars, fact sheets, and other educational materials to help healthcare providers and patients understand the science and regulation of biosimilars. The FDA also provides guidance on biosimilar development, approval, and interchangeability, to ensure that these drugs are safe and effective alternatives to reference biologics (6).

In Europe, the European Medicines Agency (EMA) has launched several initiatives to increase education and awareness about biosimilars. The EMA's Biosimilars Information Guide provides information on the science, regulation, and benefits of biosimilars. The EMA also provides guidance on biosimilar development and approval, and works with national regulatory agencies to ensure that these drugs are safe and effective alternatives to reference biologics (9).

Patient advocacy groups have also played a role in increasing education and awareness about biosimilars. For example, the Arthritis Foundation in the United States has launched several initiatives to educate patients with arthritis about biosimilars, including webinars, fact sheets, and other educational resources. The Foundation's Biosimilars Education Initiative aims to help patients understand the science and regulation of biosimilars, and to promote their safe and effective use (26).

In addition, some healthcare systems and insurance providers have implemented policies to promote the use of biosimilars. For example, the United States Veterans Health Administration (VHA) has implemented a policy to automatically substitute biosimilars for reference biologics, unless the prescriber determines that the reference biologic is medically necessary. This policy has led to significant cost savings, while maintaining high levels of patient safety and satisfaction.

Overall, recent initiatives to increase patient and provider education on biosimilars are critical to improving understanding and promoting the safe and effective use of these drugs. By addressing knowledge gaps and concerns, these initiatives can help increase adoption of biosimilars, reduce healthcare costs, and improve patient outcomes.

Future directions:

The future of biosimilars is promising, with the potential for these drugs to expand into new therapeutic areas and the development of more advanced biosimilars. With increasing pressure to reduce healthcare costs and the expiration of patents on many biologics, biosimilars are expected to play an increasingly important role in the pharmaceutical industry.

One area of potential growth for biosimilars is in the treatment of oncology and rare diseases. Many biologics used in these areas are highly expensive, making them inaccessible to many patients. Biosimilars offer an opportunity to increase access to these important therapies, while also reducing healthcare costs. In addition, the development of biosimilars for rare diseases may provide a much-needed alternative for patients with limited treatment options. (27)

Another area of potential growth for biosimilars is the development of more advanced biosimilars. Advanced biosimilars are those that go beyond the regulatory requirements for demonstrating similarity to reference biologics, and include additional data on efficacy, safety, and immunogenicity. These advanced biosimilars may offer benefits over reference biologics, including improved clinical outcomes, reduced adverse events, and increased patient adherence.

The development of advanced biosimilars is already underway, with several companies investing in this area. For example, Samsung Biopics has developed an advanced biosimilar of Enbrel (etanercept) for the treatment of rheumatoid arthritis and other autoimmune diseases. This biosimilar, called Iacovo, has demonstrated clinical equivalence to the reference biologic, while also providing additional data on efficacy and safety (28).

In addition, the development of biosimilars using new technologies, such as gene editing and cell line engineering, may further expand the potential for biosimilars in the future. These technologies offer opportunities to optimize the manufacturing process for biosimilars, reducing costs and improving quality.

Overall, the future of biosimilars is bright, with the potential for these drugs to expand into new therapeutic areas and the development of more advanced biosimilars. With increasing pressure to reduce healthcare costs and increase patient access to therapies, biosimilars offer an important solution for both patients and the healthcare industry.

Continued innovation and investment in biosimilar development are essential to ensure a sustainable and affordable healthcare system. Biosimilars have already made significant contributions to patient care and have the potential to transform the treatment landscape in the future. However, several challenges need to be overcome to fully realize the potential of biosimilars.

One of the main challenges facing biosimilar manufacturers is the high cost of development and regulatory requirements. Unlike generic drugs, biosimilars require extensive analytical, non-clinical, and clinical studies to demonstrate their similarity to the reference product. This process can be time-consuming and expensive, resulting in a significant financial burden for biosimilar manufacturers. Moreover, the regulatory requirements for biosimilars continue to evolve, necessitating ongoing investment in research and development. (8).

Another challenge facing biosimilar manufacturers is the complexity of biologic drugs. Biologics are large, complex molecules that are produced using living cells. As a result, even minor changes in the manufacturing process can result in significant changes in the final product. This complexity makes it challenging to develop biosimilars that are identical to the reference product. Furthermore, the variability inherent in biologic drugs can make it difficult to establish a clear regulatory pathway for biosimilar development (29).

Patient and provider education is also crucial to the success of biosimilars. Patients and providers must be confident that biosimilars are safe, effective, and equivalent to the reference product. However, there is often confusion and misinformation surrounding biosimilars, which can undermine their uptake. Several initiatives have been launched to increase patient and provider education, including the development of educational materials, patient advocacy groups, and biosimilar-specific conferences.

Despite these challenges, biosimilars have tremendous potential to transform the treatment landscape in the future. One area of potential growth is in the development of biosimilars for new therapeutic areas. For example, biosimilars for oncology drugs have been successful in reducing healthcare costs and improving patient access to treatment. Additionally, the development of more advanced biosimilars, such as biosimilars with improved pharmacokinetics or delivery mechanisms, may also increase their uptake.

In conclusion, the future of biosimilars is promising, but continued innovation and investment are essential to overcome the challenges facing biosimilar manufacturers. Patient and provider education is also crucial to ensure the uptake and success of biosimilars.

With the ongoing investment and innovation in biosimilar development, biosimilars have the potential to transform patient care and improve access to affordable treatments.

Conclusion:

In conclusion, biosimilars offer significant potential for improving patient access to biologic therapies while reducing healthcare costs. However, continued research and education are needed to ensure their safe and effective use in clinical practice. As the biosimilar market continues to grow, it will be important for healthcare systems, providers, and patients to work together to maximize the potential benefits of this innovative class of drugs.

Biosimilars have the potential to revolutionize the healthcare industry by increasing access to biologic drugs while reducing healthcare costs. While there are still challenges to be faced, the future of biosimilars looks promising, and continued investment and innovation in this area will be critical to realizing their full potential.

 

 

 

 

References: -

1. Biopharmaceuticals in perspective fall [Internet]. Document from Pharma-org [updated at 16^th July 2018] Available from: https://phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/A-C/ChartPack_Biopharmaceuticals_in_Perspective_Fall2020.pdf

2. Delivering on the potentials of Biosimilar medicine [Internet]. Document from EMA [updated at 1^st March 2018] Available from:https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf

3. Joshi D, Khursheed R, Gupta S, Wadhwa D, Singh TG, Sharma S, Porwal S, Gauniyal S, Vishwas S, Goyal S, Gupta G, Eri RD, Williams KA, Dua K, Singh SK. Biosimilars in Oncology: Latest Trends and Regulatory Status. Pharmaceutics. 2022 Dec 5;14(12):2721. doi: 10.3390/pharmaceutics14122721. PMID: 36559215; PMCID: PMC9784530.

4. Cargnin S, Shin JI, Genazzani AA, Nottegar A, Terrazzino S. Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials. Cancer Chemother Pharmacol. 2020 Nov;86(5):577-588. doi: 10.1007/s00280-020-04156-3. Epub 2020 Oct 1. PMID: 33005979.

5. van Aerts LA, De Smet K, Reichmann G, van der Laan JW, Schneider CK. Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union. MAbs. 2014;6(5):1155-62. doi: 10.4161/mabs.29848. PMID: 25517301; PMCID: PMC4622966.

6. Questions and Answers on Biosimilar Development and the BPCI Act Guidance for Industry [Internet]. Guidance document from US FDA [updated at 2021 September] Available from: https://www.fda.gov/media/119258/download

7. Guidelines on evaluation of biosimilars [Internet]. WHO [updated at 2022-24-12; Published at 2021-05-11] Available from: https://cdn.who.int/media/docs/default-source/biologicals/who-guidelines-on-evaluation-of-biosimilars---4-nov-2021.pdf?sfvrsn=f17799ae_5

8. Biosimilars [Internet]. Document from US FDA [updated at 03/01/2023] Available from: https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars

9. Biosimilar medicines: Overview [Internet]. Document from EMA [updated at 26/04/2023] Available from: https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview

10. Biosimilar medicines: Overview [Internet]. Document from EMA [updated at June 21- 2023] Available from: https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview

11. Łosińska K, Korkosz M, Pripp AH, Haugeberg G. Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab. Rheumatol Int. 2023 May;43(5):881-888. doi: 10.1007/s00296-023-05307-4. Epub 2023 Mar 16. PMID: 36922417; PMCID: PMC10017342.

12. Zhao Z, Zhao L, Xia G, Lu J, Shen B, Zhou G, Wu F, Hu X, Feng J, Yu S. Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study. Front Oncol. 2023 Jan 9; 12:1036906. doi: 10.3389/fonc.2022.1036906. PMID: 36698393; PMCID: PMC9868544.

13. Lu X, Hu R, Peng L, Liu M, Sun Z. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis. Front Immunol. 2021 Apr 6; 12:638444. doi: 10.3389/fimmu.2021.638444. PMID: 33889152; PMCID: PMC8055954.

14. Thill M. Biosimilar Trastuzumab in Clinical Trials: Differences or Not? Breast Care (Basel). 2019 Mar;14(1):17-22. doi: 10.1159/000496503. Epub 2019 Jan 30. PMID: 31019438; PMCID: PMC6465702.

15. Global Medicine Spending and Usage Trends: Outlook to 2025 - IQVIA [Internet]. IQVIA [updated at 28 April 2021] Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-medicine-spending-and-usage-trends-outlook-to-2025

16. Biosimilars in the EU [Internet]. IQVIA [updated at Sep 29, 2020] Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-medicine-spending-and-usage-trends-outlook-to-2025

17. Biosimilars Biological product payment [Internet] U.S. Centers for Medicare & Medicaid Services [updated at Sep 19, 2022]. Available from: https://innovation.cms.gov/initiatives/biosimilar-pirs-model/

18. Mulcahy A, Buttorff C, Finegold K, El-Kilani Z, Oliver JF, Murphy S, Jessup A. Projected US savings from biosimilars, 2021-2025. Am J Manag Care. 2022 Jul;28(7):329-335. doi: 10.37765/ajmc.2022.88809. PMID: 35852882.

19. González-Gay MA, Castañeda S, Ancochea J. Biologic Therapy in COVID-19. Arch Bronconeumol. 2021 Jan; 57:1-2. doi: 10.1016/j.arbres.2020.06.007. Epub 2020 Jun 26. PMID: 34629622; PMCID: PMC7318980.

20. The Impact of Biosimilar Competition in Europe [Internet]. IQVIA [updated at Dec, 2021] Available from: https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021.pdf 

21. Aladul MI, Fitzpatrick RW, Chapman SR. Healthcare professionals' perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study. BMJ Open. 2018 Nov 18;8(11): e023603. doi: 10.1136/bmjopen-2018-023603. PMID: 30455389; PMCID: PMC6252648.

22. Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. Drugs. 2018 Mar;78(4):463-478. doi: 10.1007/s40265-018-0881-y. PMID: 29500555; PMCID: PMC5854749.

23. Hu R, Yuan T, Wang H, Zhao J, Shi L, Li Q, Zhu C, Su N, Zhang S. Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis. Front Pharmacol. 2023 Feb 16; 14:1089272. doi: 10.3389/fphar.2023.1089272. PMID: 36874005; PMCID: PMC9979087.

24. Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis. 2019 Mar 26; 10:2040622319838443. doi: 10.1177/2040622319838443. PMID: 30937157; PMCID: PMC6435871.

25. Oskouei ST, Kusmierczyk AR. Biosimilar Uptake: The Importance of Healthcare Provider Education. Pharmaceut Med. 2021 Jul;35(4):215-224. doi: 10.1007/s40290-021-00396-7. Epub 2021 Aug 22. PMID: 34420201; PMCID: PMC8421278.

26. Baker JF, Leonard CE, Lo Re V 3rd, Weisman MH, George MD, Kay J. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Arthritis Rheumatol. 2020 Jul;72(7):1067-1071. doi: 10.1002/art.41277. Epub 2020 May 5. PMID: 32253823; PMCID: PMC7329608.

27. Kirchhoff CF, Wang XM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: Key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017 Dec;114(12):2696-2705. doi: 10.1002/bit.26438. Epub 2017 Sep 19. PMID: 28842986; PMCID: PMC5698755.

28. Chadwick L, Zhao S, Mysler E, Moots RJ. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis. Curr Rheumatol Rep. 2018 Nov 9;20(12):84. doi: 10.1007/s11926-018-0799-0. PMID: 30411183; PMCID: PMC6244902.

29. Mulcahy AW, Hlavka JP, Case SR. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. Rand Health Q. 2018 Mar 30;7(4):3. PMID: 30083415; PMCID: PMC6075809.